| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Shanghai Shyndec Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥11.00 |
| 52 Week High | CN¥12.87 |
| 52 Week Low | CN¥7.61 |
| Beta | 0.16 |
| 11 Month Change | -6.22% |
| 3 Month Change | 4.27% |
| 1 Year Change | 6.28% |
| 33 Year Change | 14.58% |
| 5 Year Change | 31.89% |
| Change since IPO | 566.79% |
Recent News & Updates
Is Shanghai Shyndec Pharmaceutical (SHSE:600420) Using Too Much Debt?
Aug 23
Improved Earnings Required Before Shanghai Shyndec Pharmaceutical Co., Ltd. (SHSE:600420) Stock's 33% Jump Looks Justified
May 06Recent updates
Is Shanghai Shyndec Pharmaceutical (SHSE:600420) Using Too Much Debt?
Aug 23Improved Earnings Required Before Shanghai Shyndec Pharmaceutical Co., Ltd. (SHSE:600420) Stock's 33% Jump Looks Justified
May 06Is Shanghai Shyndec Pharmaceutical (SHSE:600420) A Risky Investment?
Apr 30Solid Earnings May Not Tell The Whole Story For Shanghai Shyndec Pharmaceutical (SHSE:600420)
Apr 05Shareholder Returns
| 600420 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 9.7% | 1.1% | 5.4% |
| 1Y | 6.3% | -17.9% | -16.2% |
Return vs Industry: 600420 exceeded the CN Pharmaceuticals industry which returned -17.9% over the past year.
Return vs Market: 600420 exceeded the CN Market which returned -16.2% over the past year.
Price Volatility
| 600420 volatility | |
|---|---|
| 600420 Average Weekly Movement | 5.0% |
| Pharmaceuticals Industry Average Movement | 5.1% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in CN Market | 8.4% |
| 10% least volatile stocks in CN Market | 3.7% |
Stable Share Price: 600420 has not had significant price volatility in the past 3 months.
Volatility Over Time: 600420's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 11,608 | Yong Liu | www.shyndec.com |
Shanghai Shyndec Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical intermediates, raw materials, and pharmaceutical preparations in China and internationally. The company’s pharmaceutical intermediate products primarily includes 7-ACA, 6-APA, penicillin industrial salt, etc.; API products for anti-infection applications comprising azithromycin, amoxicillin, potassium clavulanate, ceftriaxone sodium, etc., as well as urine source biochemical products and other characteristic raw materials; pharmaceutical preparations, such as cardiovascular and cerebrovascular drugs that comprises enalapril maleate tablets and nifedipine controlled-release tablets; and anti-aging drugs, including cefuroxime axetil and cefuroxime sodium; and metabolic and endocrine drugs consist if methylprednisolone sodium succinate through injections. Its products portfolio covers systemic anti-infection, heart and brain blood vessels, anti-tumor and immunomodulators, central nervous system, hormones, genitourinary system, digestive tract and metabolism, respiratory system, and other therapeutic areas in various dosage forms, such as tablets, capsules, powder injections, small volume injections, granules, suspensions, suppositories, and ointments.
Shanghai Shyndec Pharmaceutical Co., Ltd. Fundamentals Summary
| 600420 fundamental statistics | |
|---|---|
| Market cap | CN¥14.07b |
| Earnings (TTM) | CN¥1.07b |
| Revenue (TTM) | CN¥11.59b |
13.8x
P/E Ratio1.3x
P/S RatioIs 600420 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 600420 income statement (TTM) | |
|---|---|
| Revenue | CN¥11.59b |
| Cost of Revenue | CN¥7.20b |
| Gross Profit | CN¥4.38b |
| Other Expenses | CN¥3.32b |
| Earnings | CN¥1.07b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.79 |
| Gross Margin | 37.85% |
| Net Profit Margin | 9.20% |
| Debt/Equity Ratio | 7.0% |
How did 600420 perform over the long term?
See historical performance and comparison